PRS by initial treatment regimen (n = 272)
| Characteristic . | 3-year postrelapse survival ± SE % . | ||
|---|---|---|---|
| Standard PII, n = 163 (n) . | Augmented PII, n = 109 (n) . | Log-rank P . | |
| Timing from diagnosis, mo | |||
| < 18 | 25.5 ± 6.1 (56) | 21.6 ± 7.2 (45) | 0.97 |
| 18-35 | 40.0 ± 6.8 (59) | 31.5 ± 9.8 (30) | 0.47 |
| ≥ 36 | 55.0 ± 7.7 (48) | 62.2 ± 11.0 (34) | 0.68 |
| Site | |||
| All | 39.2 ± 4.1 (163) | 36.4 ± 5.7 (109) | 0.72 |
| Marrow | 33.0 ± 4.7 (112) | 24.1 ± 5.8 (74) | 0.33 |
| (±EMD) | |||
| Isolated CNS | 48.8 ± 9.7 (36) | 56.1 ± 10.7 (30) | 0.51 |
| Age at initial diagnosis, y | |||
| 1-9 | 51.1 ± 6.6 (67) | 44.3 ± 8.3 (39) | 0.46 |
| 10-15 | 33.6 ± 5.8 (77) | 39.2 ± 9.2 (55) | 0.50 |
| 16-20 | 21.1 ± 8.4 (19) | 0 (15) | 0.38 |
| Lineage | |||
| B | 41.9 ± 5.0 (112) | 38.5 ± 6.4 (81) | 0.79 |
| T | 28.2 ± 9.0 (28) | 31.8 ± 15.1 (18) | 0.63 |
| Characteristic . | 3-year postrelapse survival ± SE % . | ||
|---|---|---|---|
| Standard PII, n = 163 (n) . | Augmented PII, n = 109 (n) . | Log-rank P . | |
| Timing from diagnosis, mo | |||
| < 18 | 25.5 ± 6.1 (56) | 21.6 ± 7.2 (45) | 0.97 |
| 18-35 | 40.0 ± 6.8 (59) | 31.5 ± 9.8 (30) | 0.47 |
| ≥ 36 | 55.0 ± 7.7 (48) | 62.2 ± 11.0 (34) | 0.68 |
| Site | |||
| All | 39.2 ± 4.1 (163) | 36.4 ± 5.7 (109) | 0.72 |
| Marrow | 33.0 ± 4.7 (112) | 24.1 ± 5.8 (74) | 0.33 |
| (±EMD) | |||
| Isolated CNS | 48.8 ± 9.7 (36) | 56.1 ± 10.7 (30) | 0.51 |
| Age at initial diagnosis, y | |||
| 1-9 | 51.1 ± 6.6 (67) | 44.3 ± 8.3 (39) | 0.46 |
| 10-15 | 33.6 ± 5.8 (77) | 39.2 ± 9.2 (55) | 0.50 |
| 16-20 | 21.1 ± 8.4 (19) | 0 (15) | 0.38 |
| Lineage | |||
| B | 41.9 ± 5.0 (112) | 38.5 ± 6.4 (81) | 0.79 |
| T | 28.2 ± 9.0 (28) | 31.8 ± 15.1 (18) | 0.63 |
EMD indicates extramedullary disease; and CNS, central nervous system.